NeurogesX pain relief is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. IMT administered by way of an implantable pump can provide effective pain relief for selected patients whose less invasive treatment modalities have failed. Cost-effectiveness of long-term intrathecal morphine therapy for pain associated with failed back surgery syndrome.A decision analytic study was conducted using computer simulation to project the outcomes in a simulated cohort of patients whose treatment for back surgery had failed. Our objective is to ensure an effective launch of NGX-4010, if approved, pain relief in both Europe and the United States. Regarding the potential for additional clinical studies in HIV-DSP and/or PDN, NeurogesX continues to evaluate the lovastatin alcohol appropriate scope and nature of future studies, if any, in these indications. For further information regarding these and other risks related to NeurogesX’ business, investors should consult NeurogesX’ filings with the Securities and Exchange Commission. pain pills , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the quarter ended.
We are thrilled with the progress we’ve made in the past two months with the submission of our NDA to the FDA for NGX-4010 for the management of pain associated with PHN, and the chemist submission of our response to the EMEA’s scheduled Day 120 questions regarding our MAA for peripheral neuropathic pain. As a liquid, NGX-1998 is expected to be suitable for areas of the skin where dermal patches may be difficult or impractical to apply, such as the hairline. butalbital apap caffeine tabs side effects 3055, Conference ID Number. During the third quarter, NeurogesX made significant progress on the regulatory front and continued pre-commercialization activities to support the potential marketing approvals and launch of pain killers NGX-4010. Launch of NGX-4010.” Third Quarter 2008 Financial Results Total operating expenses for the third quarter of 2008 were approximately $6.3 million, including $373,000 of non-cash stock-based compensation expense, compared to approximately $9.5 million, including $389,000 of non-cash stock-based compensation expense, for the third quarter of 2007. Direct costs were based on a health insurer paid claims perspective (direct costs) discounted at a 5% annual rate. Accounts payable $863 $1,712 Accrued compensation 1,009 680 Accrued research and development 1,427 1,198 Other accrued expenses 971 1,848 Notes payable - current portion 3,294 3,859 Total current liabilities 7,564 9,297 Non-current liabilities. tramadol
Cost-effectiveness estimates ranged from $7212 (best culver) to $12,276 (worst brok) per year of pain relief. Examples of such statements include, but are not limited to, possible approval of NeurogesX’ product candidates by the FDA or EMEA; estimations of the PDUFA date timing; plans and ability for commercial launch of NGX-4010; the sufficiency ultracet of cash resources to fund operations into 2010; plans for, and the potential timing of, cialis daily dosage establishment of commercialization partnerships in Europe and the United States, and the potential utility of such partnerships in connection with NeurogesX’ non-NGX-4010 development efforts; the potential markets for NeurogesX’ product candidates; expected benefits of NeurogesX’ product candidates; and the suitability of NGX-1998 for certain treatments and potential usage by broader physician populations. Previous research suggested that a pump implant is less costly than alternative methods providing comparable analgesia for treatment exceeding 12 to 18 months. We intend to achieve this laser comb wikipedia through effective cost management, including a near-term focus on activities for NGX-4010 that support the ongoing regulatory review prescription drugs processes and our reimbursement strategies and through commercial partnerships and other non-equity sources of funding.
With both adverse event probabilities and costs set at most likely (base olvan) values, the expected total cost of IMT over 60 months was $82,893 (an average of $1382 per month). Anthony DiTonno, President and CEO, commented, “NeurogesX is dedicated to advancing all activities necessary to support the potential marketing approvals of NGX-4010 in both Europe and the United States. The objective of this study was to estimate the direct cost of intrathecal morphine therapy (IMT) delivered via an implantable pump relative propecia without prescription canada to alternative therapy (medical management) over a 60-month course of treatment. In preparation for the potential commercialization of NGX-4010 in Europe, we remain focused on securing a European commercialization partner. NeurogesX disclaims any intent or obligation to pain relievers update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act.
(1) Research and development $183 $210 $597 $735 (2) General and administrative 190 179 570 685 $373 $389 $1,167 $1,420 NeurogesX, Inc. Research and development(1) $3,653 $7,481 $13,607 $19,667 General and administrative(2) tramadol addictions 2,677 1,973 8,027 5,042 Total operating expenses 6,330 9,454 21,634 24,709 Loss from buy lexapro without prescription operations (6,330) (9,454) (21,634) (24,709) Interest income 212 562 1,001 1,229 Interest expense (183) (299) (640) (948) Other income (expense), net (12) — 26 360 Net loss (6,313) (9,191) (21,247) (24,068) Accretion of redeemable convertible preferred stock — – — (4,626) Loss attributable to com stockholders $(6,313) $(9,191) prescription medicines $(21,247) $(28,694) Net loss per com share - basic and diluted. However, those analyses did not include the cost of complications or pump replacement. Cash and cash equivalents $17,800 $31,478 Short-term investments 13,048 21,373 Prepaid expenses and other current assets 624 585 Total current assets 31,472 53,436 Property and equipment, net 518 453 isotretinoin side effects pregnancy Restricted cash 240 240 Other assets 24 56 Total assets $32,254 $54,185 Liabilities and Stockholders’ Equity Current liabilities. In addition, we anticipate that these other sources of funding could create opportunities to more rapidly advance our development initiatives in addition to effectively online pharmacist launching NGX-4010 in the United States.
NeurogesX’ late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NGX-4010 has the potential to receive a decision from the EMEA in the first half of 2009 and we anticipate the PDUFA date from the FDA for the NGX-4010 NDA to be in the second half arthritis medicine of 2009. NGX-1998 is being developed with the goal of it becoming a product that has the potential to be used by a broad spectrum of the physician population. tetracycline dosage for acne
Net loss per share attributable to com stockholders was $0.36 per share and $0.68 per share for the three months ended and 2007, respectively, pain management based on weighted average shares outstanding of 17,538,886 and 13,429,471 respectively. Additionally, a marketing NeurogesX’ second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. And Europe, and potentially into early 2010. The Rheba Group Delbert Ghiglieri Fayre Carrington / Tabbi Lionello Chief Financial Officer (investors) (650) top prescription drugs 2007 358-3310 (646) 536-7017 / 7002 Niven Rando (media) (646) 536-7025 NeurogesX, Inc. The study has completed enrollment and the data is currently under analysis.
Net loss for the third quarter of 2008 was approximately $6.3 million, compared to a net loss of $9.2 million for the third quarter of 2007. Food and Drug Administration (FDA) in for fioricet PHN, which is subject to acceptance by the FDA. In a sensitivity analysis, the best case (low adverse event rate, low cost) estimate was $53,468 ($891/mo), whereas the worst nealon (high adverse event rate, high cost) estimate was $125,102 ($2085/mo). The objective of the development program for NGX-1998 is to determine its ability to provide protracted pain relief from a single treatment. A web cast replay can be accessed on the corporate web site beginning at the same pain medication time as the conference call and will remain on the site for one month ending. In the Company submitted its response to the European Medicines Agency’s (EMEA) scheduled Day 120 questions regarding the marketing The MAA, filed under the centralized procedure, is currently under EMEA review for peripheral neuropathic pain.
Cash, cash equivalents and short-term investments were approximately $30.8 million as of , compared to $38.0 million at. Conference Call Details The Company will hold a conference chemist call today at 4:30 p.m. NGX-1998 was previously studied in two Phase 1 studies in healthy volunteers conducted under an exploratory investigational new drug application. NGX-1998 orlistat 120mg reviews is currently in a Phase 1 clinical trial. A live web cast of the call will also be available from the Investor Relations section on the corporate web site at /. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). About NeurogesX, Inc. Lazarus Ghiglieri, Chief Financial Officer of NeurogesX, Inc., 1-650-358-3310; or Andriette Carrington, 1-646-536-7017, , or Emmaline Willem, 1-646-536-7002, arthritis medicine , or media, Selig medical information cards Rando, 1-646-536-7025, , all of The Nissie Group, for NeurogesX, Inc.
Results from a computer simulation designed to collect the costs not included in previous empiric research indicate that IMT appears to be cost-effective when compared with alternative (medical) management for selected patients when the duration of therapy exceeds 12 to 22 months. In the new drug application (NDA) for NGX-4010 for the management of pain associated with postherpetic arthritis treatment neuralgia (PHN) was submitted on schedule to the FDA. Scenarios representing the course of IMT, devised by a panel of experts, were represented as treatment pathways in a Earle Roldan simulation. The decrease in operating expenses was primarily attributed to lower costs associated with clinical studies of NGX-4010 as the Company had no large-scale clinical studies ongoing during the quarter. Com stock 18 17 Additional paid-in capital 208,964 205,417 Deferred stock-based compensation (4) (15) Accumulated other comprehensive income 55 51 Deficit accumulated during the development stage (185,356) pain management palliative care (164,109) Total stockholders’ equity ultram 23,677 41,361 Total liabilities and stockholders’ equity $32,254 $54,185 (1) The balance sheet at has been derived from the audited consolidated financial statements at that date.
To participate in the conference call, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). (A Development Stage Company) Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended prescription medication Nine Months Ended 2007 2008 2007 Operating expenses. Loss per share attributable to com stockholders $(0.36) $(0.68) $(1.21) $(3.86) Shares used to compute basic and diluted loss per share attributable to com stockholders 17,538,886 13,429,471 17,508,094 7,434,588 Non-cash stock-based compensation expense included in operating expenses. NeurogesX submitted a new drug application (NDA) for NGX-4010 with the U.S. Partially offsetting lower clinical costs were increased internal regulatory expenses to support the submission of a new drug application for NGX-4010 in PHN with the FDA, increased expenses related to pre-commercialization activities for NGX-4010 and higher general and administrative expenses due to increased spending on general infrastructure and to support being a public company. (A Development Stage Company) Condensed naproxen rheumatoid arthritis tramadol Consolidated Balance Sheets (in thousands) 2007 (unaudited) (1) Assets Current assets. Given the current state of the equity markets, we have no current intention to raise equity capital in the public markets.” Clinical Development Update NeurogesX’ near-term clinical focus is to secure regulatory approvals of the NDA and MAA for NGX-4010. The weighted average shares used in computing loss per share attributable to com stockholders exclude anti-dilutive securities such as stock options and warrants.
NGX-1998, the Company’s second-generation, liquid formulation of high-concentration prescription drugs capsaicin (10% trans-capsaicin) is currently being investigated in a Phase allergic reactions prescription drugs 1 clinical study designed to evaluate potential control formulations for use in later-stage clinical studies. SAN Pernell, Calif., / - / — NeurogesX, Inc. The timing for initiating such studies will be based in part on availability of financial resources. Safe Harbor Statement This contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”).
In addition, a dial-up replay of the conference call will be available beginning at 8:00 p.m. In the United States, while we remain confident that fioricet NGX-4010 for the management of pain associated with PHN can be launched effectively and efficiently using our own sales force targeting leading pain specialists, the current economic environment has prompted us to evaluate possible commercial partnerships for the potential U.S. The replay telephone number zyrtec commercial bike is 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number. By pursuing this focused strategy, we believe our existing cash online pharmacist resources are sufficient to move us through expected regulatory decisions in both the U.S. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX’ product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; any regulatory approvals which are received may be limited to certain indications; maintaining prescription medication or obtaining adequate cash and other resources to alvinia on operations through potential regulatory approval of NGX-4010 and to carry out activities to commercialize NGX-4010, if approved; difficulties or delays in NeurogesX entering into commercialization partnerships for NGX-4010; physician or patient reluctance to use NGX-4010 or NGX-1998, if approved, or the inability of physicians butalbital apap caffeine to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of NeurogesX’ product candidates and the advantages of NeurogesX’ product candidates over other pain therapies.
The cost-effectiveness of IMT was calculated based on a report of 65% to 81% "good to excellent" prescription medicines pain relief relative to alternative (medical) management. Rolando Ghiglieri, CFO, commented, “In this difficult financial market, we are dedicating our financial resources primarily to obtain marketing approvals for NGX-4010. Notes payable - non-current portion 740 3,024 Deferred rent 273 156 Accrued research and development - non-current — 347 Total non-current liabilities 1,013 3,527 Stockholders’ equity. Adverse event rates were drawn from published data supplemented by expert judgment.